文献速递生殖医学

微流控技术在体外受精中的应用:从科学到临床验证

Microfluidics for in vitro fertilization: from science to clinical validation.
PubMed 文献 · Hum Reprod Update · 2026-01-01

本文为叙述性综述,分析微流控技术在体外受精中的发展、专利与临床试验现状。检索2013-2025年文献及2000-2025年专利,发现近20年微流控相关专利达1405项,但仅19项临床试验自2009年启动,主要集中于精子分选和胚胎培养。

要点

  • 近5年超130篇微流控IVF相关论文,聚焦配子处理、胚胎培养和冷冻保存。
  • 仅19项临床试验自2009年启动,主要验证微流流控精子分选和胚胎培养。
  • 临床转化障碍包括长期结局数据缺乏、结果标准化和监管挑战。

核心结论

  • 微流控技术在IVF领域专利增长迅速,但临床验证仍有限,主要集中于精子分选和胚胎培养。

研究设计与样本

  • 叙述性综述,检索PubMed和Google Scholar近十年(2013-2025)文献,Clinicaltrials.gov临床试验,以及lens.org和espacenet.com专利(2000-2025)。

主要发现

  • 近5年有超过130篇出版物提出新的微流控解决方案,包含动物模型和人类临床前验证数据。
  • 过去20年微流控相关专利达1405项,涉及辅助生殖周期不同步骤。
  • 自2009年起仅19项临床试验启动,主要研究微流控精子分选和胚胎培养系统。

临床怎么用

  • 微流控精子分选可能改善精子质量和受精率,但需更多长期临床结局数据支持。
  • 微流控胚胎培养系统相对于传统培养环境的获益尚需进一步研究确立。

局限性

  • 临床验证研究数量有限,结果在不同患者群体间的标准化不足,监管路径复杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This narrative review analyses the development of microfluidic technologies specifically applied to the IVF treatment, and their translation into clinical solution. OBJECTIVE AND RATIONALE: Starting with an analysis of the latest scientific publications, the patent scenario and the current clinical trials were analysed aiming to identify the most developed applications, the challenges, and barriers for regulatory approval and clinical validation in different countries. SEARCH METHODS: Searches were completed in English, by using a combination of these keywords (exceptions are included in the text in the different sections): Microfluidic, IVF, Assisted, clinical, fertility, human fertility, women fertility, reproduction, pregnancy, Assisted Reproductive Technology. These were used for previously published reviews and scientific journal papers using PubMed (National Center for Biotechnology Information at the U.S. National Library of Medicine), and Google Scholar, limited to the last decade (2013-2025); for completed or ongoing clinical trials using Clinicaltrials.gov; for existing patents and intellectual properties commercialization using lens.org, and crosschecked on espacenet.com from 2000 to 2025. OUTCOMES: It is approximately 20 years since the design of the first microfluidic systems for IVF. In the last 5 years, there have been over 130 publications proposing new microfluidic solutions, with pre-clinical validation data in animal models and humans. Our analysis highlighted three main areas of development that are discussed in terms of trends and advancements in oocyte and sperm processing and handling; proposed solutions to support in vitro embryo development; and microfluidic-based approaches and techniques for cryopreservation and female fertility preservation. In the last 20 years, progression of the microfluidic technology and improvement of manufacturing processes have led to an exponential rise of patents (1405) where microfluidics is applied to different steps of the assisted conception cycle. However, of these innovative techniques, only a limited number have progressed to clinical validation (19 trials commenced since 2009) and these have focused primarily on microfluidic sperm sorting and selection with multiple trials investigating its effectiveness in enhancing sperm quality and fertilization rates, and microfluidic embryo culture systems, where additional research is still needed to establish benefits over traditional culture environments. The key barriers to adoption include the need for long-term clinical outcome data, standardization of results across various patient populations, and regulatory challenges. We summarize the pathways needed to ensure compliance with quality standards and regulations in different countries. This analysis evaluates the different clinical trial requirements and challenges for participant recruitment, as well as study design complexity, and the definition of achievable endpoints and establishment of appropriate control groups or comparators. WIDER IMPLICATIONS: Finally, this review highlights complementary technologies recently combined with microfluidics (e.g. automatic and artificial intelligence-powered imaging, in situ non-invasive metabolic sensing) which can guarantee a more precise and safe handling of biological samples, favour automation of sample processing (e.g. gametes), and provide new information and higher level of control of the laboratory techniques used by clinics to treat patients in the next 5-10 years. REGISTRATION NUMBER: N/A.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Pensabene V, Agate F, Santos Miranda A, et al. Microfluidics for in vitro fertilization: from science to clinical validation. Hum Reprod Update. 2026. PMID: 41349964. doi:10.1093/humupd/dmaf028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。